

Resource Summary Report

Generated by [RRID](#) on Aug 28, 2026

MDA-MB-361

RRID:CVCL_0620

Type: Cell Line

Proper Citation

RRID:CVCL_0620

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0620

Proper Citation: RRID:CVCL_0620

Description: Cell line MDA-MB-361 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Breast adenocarcinoma

Defining Citation: [PMID:730202](#), [PMID:833871](#), [PMID:3518877](#), [PMID:6935474](#), [PMID:7272986](#), [PMID:9671407](#), [PMID:10862037](#), [PMID:10969801](#), [PMID:11044355](#), [PMID:11343771](#), [PMID:12800145](#), [PMID:15677628](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:17334996](#), [PMID:18516279](#), [PMID:19582160](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:22585861](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:29273624](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: PI3K genetic alteration cell panel (ATCC TCP-1028)., Part of: MD Anderson Cell Lines Project., Part of: KuDOS 95 cell line panel., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: EGFR genetic alteration cell panel (ATCC TCP-1027)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: MDA-MB-361

Synonyms: MDA-MB 361, MDA MB 361, MDA-MB361, MDAMB361, MDA-361, MDA361, MB361, MD Anderson-Metastatic Breast-361

Cross References: BTO:BTO_0001569, CLO:CLO_0007636, EFO:EFO_0001211, CLDB:cl3406, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-27, BCRC:60549, BioGRID_ORCS_Cell_line:1048, BioSample:SAMN03472909, BioSample:SAMN10987900, cancercellines:CVCL_0620, CCRID:1101HUM-PUMC000381, Cell_Model_Passport:SIDM00528, ChEMBL-Cells:ChEMBL3308405, ChEMBL-Targets:ChEMBL614129, CLS:305267, Cosmic:687495, Cosmic:809235, Cosmic:871147, Cosmic:904379, Cosmic:908121, Cosmic:934527, Cosmic:979709, Cosmic:997919, Cosmic:1000124, Cosmic:1010928, Cosmic:1017160, Cosmic:1018464, Cosmic:1046933, Cosmic:1047695, Cosmic:1136355, Cosmic:1176627, Cosmic:1287895, Cosmic:1289397, Cosmic:1308994, Cosmic:1348961, Cosmic:1434953, Cosmic:1523777, Cosmic:1603220, Cosmic:1609461, Cosmic:2165011, Cosmic:2301529, Cosmic-CLP:908121, DepMap:ACH-000934, ECACC:92020423, EGA:EGAS000001000610, EGA:EGAS000001000978, EGA:EGAS000001002554, GDSC:908121, GEO:GSM73751, GEO:GSM115119, GEO:GSM155208, GEO:GSM186437, GEO:GSM186438, GEO:GSM186439, GEO:GSM217587, GEO:GSM274655, GEO:GSM344350, GEO:GSM344400, GEO:GSM350546, GEO:GSM421875, GEO:GSM481306, GEO:GSM783952, GEO:GSM827280, GEO:GSM847402, GEO:GSM847494, GEO:GSM887296, GEO:GSM888371, GEO:GSM1008906, GEO:GSM1053728, GEO:GSM1172890, GEO:GSM1172980, GEO:GSM1238121, GEO:GSM1264070, GEO:GSM1264072, GEO:GSM1264112, GEO:GSM1264114, GEO:GSM1374653, GEO:GSM1374654, GEO:GSM1374655, GEO:GSM1401664, GEO:GSM1670082, GEO:GSM2258758, GEO:GSM2258759, GEO:GSM2258760, GEO:GSM2258761, GEO:GSM2258762, GEO:GSM2258763, GEO:GSM2258764, GEO:GSM2258765, GEO:GSM2258766, GEO:GSM2258767, GEO:GSM2258768, GEO:GSM2258769, GEO:GSM2258770, GEO:GSM2258771, GEO:GSM2258772, GEO:GSM2258773, GEO:GSM2258774, GEO:GSM2258775, GEO:GSM2258935, GEO:GSM2258936, GEO:GSM2258937, IARC_TP53:18373, IARC_TP53:21128, LiGeA:CCL_872, LINCS_HMS:50331, LINCS_LDP:LCL-1468, NCBI_Iran:C433, PharmacDB:MDAMB361_902_2019, PRIDE:PXD030304, Progenetix:CVCL_0620, PubChem_Cell_line:CVCL_0620, SLKBase:3600, Wikidata:Q54904626

ID: CVCL_0620

Record Creation Time: 20220427T220755+0000

Record Last Update: 20260815T234601+0000

Ratings and Alerts

No rating or validation information has been found for MDA-MB-361.

No alerts have been found for MDA-MB-361.

Data and Source Information

Usage and Citation Metrics

We found 520 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Perurena N, et al. (2026) EZH2 Inhibitors Sensitize Breast Cancer to HER2 Kinase Inhibitors through Cooperative Effects on YAP and Proapoptotic Regulators. *Cancer research*, 86(6), 1467.

Gao A, et al. (2026) Integrated Multiomic Profiling Identifies BRD8/EP400 as a Pivotal Chromatin Module Mediating Anti-HER2 Response in HR+/HER2+ Breast Cancer. *Cancer research*, 86(13), 3287.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. *Cell chemical biology*, 33(6), 785.

Cheng TC, et al. (2025) Fibroblast growth factor receptor four inhibitor FGF401 improves the efficacy of trastuzumab in FGFR4-overexpressing breast cancer cells. *International journal of cancer*, 156(8), 1606.

Alam R, et al. (2025) Bone-Induced HER2 Promotes Secondary Metastasis in HR+/HER2- Breast Cancer. *Cancer discovery*, 15(4), 818.

Michel M, et al. (2025) Noninvasive Multicancer Detection Using DNA Hypomethylation of LINE-1 Retrotransposons. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(7), 1275.

Olsen SN, et al. (2025) Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer. *Cell reports. Medicine*, 6(7), 102192.

Zidel A, et al. (2025) Modulation of HER2 internalization enhances single-dose antibody-drug potency in HER2+ gastric cancer. *Scientific reports*, 15(1), 16964.

Mahdi AF, et al. (2025) Pre-Clinical Rationale for Amcenestrant Combinations in HER2+/ER+ Breast Cancer. *International journal of molecular sciences*, 26(2).

Lombardi V, et al. (2025) PatientProfiler: building patient-specific signaling models from proteogenomic data. *Molecular systems biology*, 21(12), 1845.

Nagahashi M, et al. (2025) An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia. *Cancer research communications*, 5(6), 981.

Pequerul R, et al. (2025) Inter- and intra-tumoral ALDH1 heterogeneity in breast cancer identifies therapeutic opportunities for ALDH1A-specific inhibitors. *Cell chemical biology*.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8⁺ T_H1 cell progenitor expansion toward immune memory and systemic anti-tumor immunity. *Cancer cell*.

Montero-Vergara J, et al. (2024) GRB2 is a BECN1 interacting protein that regulates autophagy. *Cell death & disease*, 15(1), 14.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. *Developmental cell*, 59(5), 579.

Leuzzi G, et al. (2024) SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. *Cell*, 187(4), 861.

Moyer CL, et al. (2024) IRX4204 Induces Senescence and Cell Death in HER2-positive Breast Cancer and Synergizes with Anti-HER2 Therapy. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(11), 2558.

Mannion J, et al. (2024) A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. *Immunity*, 57(7), 1514.

Rybinska I, et al. (2024) SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness. *International journal of cancer*.